Clinical Trials Browser

Phase 2 × Ovarian Neoplasm Epithelial × Bortezomib × Clear all

NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Phase 2 Unknown

Ovarian Neoplasm Epithelial